Keyphrases
ErbB
100%
Melanoma Treatment
100%
BRAF Inhibitor (BRAFi)
100%
Melanoma Cells
55%
Canertinib
44%
Melanoma
33%
Vemurafenib
33%
Epidermal Growth Factor Receptor
22%
BRAF Wild Type
22%
BRAF V600E mutant
22%
BRAF mutant
22%
BRAF-mutant Melanoma
22%
Antiproliferative Activity
11%
ErbB2
11%
No Significant Difference
11%
Induced Apoptosis
11%
Mutant Cells
11%
Downstream Signaling
11%
Neuregulin-1 (NRG1)
11%
ErbB4
11%
Growth Inhibition
11%
Kinase Inhibitor
11%
Gefitinib
11%
Dual Inhibition
11%
Combination Treatment
11%
Enhancement Effect
11%
Melanoma Patients
11%
Mutant Lines
11%
Sub-G1 Arrest
11%
ErbB3
11%
ErbB Kinase
11%
Erlotinib
11%
Inhibition Strategies
11%
Lapatinib
11%
ErbB Signaling Pathway
11%
NRG4
11%
Irreversible Tyrosine Kinase Inhibitor
11%
BRAF Inhibitor Resistance
11%
Enhanced Antitumor Activity
11%
Neuregulin 3
11%
Medicine and Dentistry
Nodular Melanoma
100%
Canertinib
66%
Melanoma Cell
50%
Neu Differentiation Factor
50%
Vemurafenib
50%
Cell Line
33%
Melanoma Cell Line
33%
Epidermal Growth Factor Receptor
33%
Programmed Cell Death
16%
Kinase
16%
Signal Transduction
16%
Cell Mutant
16%
Phosphotransferase Inhibitor
16%
Gefitinib
16%
Antineoplastic Activity
16%
Antiproliferative Activity
16%
G1/S Transition
16%
Tyrosine-Kinase Inhibitor
16%
Erlotinib
16%
Lapatinib
16%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Canertinib
36%
Neu Differentiation Factor
27%
Vemurafenib
27%
Epidermal Growth Factor Receptor
18%
Antitumor Activity
9%
Phosphotransferase Inhibitor
9%
Gefitinib
9%
Protein Tyrosine Kinase Inhibitor
9%
Erlotinib
9%
Lapatinib
9%